Literature DB >> 16107155

Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

Guangrong Zheng1, Linda P Dwoskin, Agripina G Deaciuc, Seth D Norrholm, Peter A Crooks.   

Abstract

(-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function. VMAT2 is a target for the development of treatments for methamphetamine abuse. Structural modification of lobeline affords the defunctionalized analogues meso-transdiene (MTD) and lobelane, which have high potency and selectivity for VMAT2. To establish the structure-activity relationships within this novel class of VMAT2 ligands, specific stereochemical forms of MTD, lobelane, and other structurally related analogues have been synthesized. These compounds have been evaluated for inhibition of [(3)H]nicotine ([(3)H]NIC) binding (alpha4beta2 nAChR), [(3)H]methyllycaconitine ([(3)H]MLA) binding (alpha7 nAChR), and [(3)H]dihydrotetrabenazine ([(3)H]DTBZ) binding (VMAT2). Generally, all of these analogues had lower affinities at alpha4beta2 and alpha7 nAChRs compared to lobeline, thereby increasing selectivity for VMAT2. The following structural modifications resulted in only modest changes in affinity for VMAT2, affording analogues that were less potent than the lead compound, lobelane: (1) altering the stereochemistry at the C-2 and C-6 positions of the piperidino ring, (2) varying unsaturation in the piperidino C-2 and C-6 substituents, (3) introducing unsaturation into the piperidine ring, (4) ring-opening or eliminating the piperidine ring, and (5) removing the piperidino N-methyl group. Furthermore, incorporating a quaternary ammonium group into defunctionalized lobeline molecules in the cis-series resulted in significant loss of affinity for VMAT2, whereas only a modest change in affinity was obtained in the trans-series. The most potent (K(i) = 630 nM) and VMAT2-selective compound evaluated was the N-methyl-2,6-cis-bis(naphthaleneethyl)piperidine analogue (1-NAP-lobelane), in which the phenyl groups of lobelane were replaced with 1-naphthyl moieties. Thus, initial structure-activity relationship studies reveal that the most promising structural changes to the lobeline molecule that lead to enhancement of VMAT2 affinity and selectivity are defunctionalization, affording lobelane and MTD, and replacement of the phenyl rings of lobelane with other aromatic moieties that have a pi-extended structure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107155      PMCID: PMC3617589          DOI: 10.1021/jm0501228

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

Review 1.  A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse.

Authors:  Linda P Dwoskin; Peter A Crooks
Journal:  Biochem Pharmacol       Date:  2002-01-15       Impact factor: 5.858

2.  Lobeline attenuates locomotor stimulation induced by repeated nicotine administration in rats.

Authors:  Dennis K Miller; Steven B Harrod; Thomas A Green; Mei-Yee Wong; Michael T Bardo; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2003-01       Impact factor: 3.533

3.  Methamphetamine rapidly decreases vesicular dopamine uptake.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  Lobeline attenuates d-methamphetamine self-administration in rats.

Authors:  S B Harrod; L P Dwoskin; P A Crooks; J E Klebaur; M T Bardo
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

5.  Lobeline inhibits nicotine-evoked [(3)H]dopamine overflow from rat striatal slices and nicotine-evoked (86)Rb(+) efflux from thalamic synaptosomes.

Authors:  D K Miller; P A Crooks; L P Dwoskin
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

6.  Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

7.  Lobeline inhibits the neurochemical and behavioral effects of amphetamine.

Authors:  D K Miller; P A Crooks; L Teng; J M Witkin; P Munzar; S R Goldberg; J B Acri; L P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

8.  Lobeline does not serve as a reinforcer in rats.

Authors:  Steven B Harrod; Linda P Dwoskin; Thomas A Green; Brenda J Gehrke; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2002-11-30       Impact factor: 4.530

9.  VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET.

Authors:  Raúl De La Fuente-Fernández; Sarah Furtado; Mark Guttman; Yoshiaki Furukawa; Chong S Lee; Donald B Calne; Thomas J Ruth; A Jon Stoessl
Journal:  Synapse       Date:  2003-07       Impact factor: 2.562

10.  Characterization of a series of 3-amino-2-phenylpropene derivatives as novel bovine chromaffin vesicular monoamine transporter inhibitors.

Authors:  Rohan P Perera; D Shyamali Wimalasena; Kandatege Wimalasena
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

View more
  40 in total

1.  Acute and chronic methylphenidate alters prefrontal cortex neuronal activity recorded from freely behaving rats.

Authors:  R Layla Salek; Catherine M Claussen; Adriana Pérez; Nachum Dafny
Journal:  Eur J Pharmacol       Date:  2012-01-25       Impact factor: 4.432

2.  Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake.

Authors:  Derong Ding; Justin R Nickell; Agripina G Deaciuc; Narsimha Reddy Penthala; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2013-08-11       Impact factor: 3.641

3.  Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2.

Authors:  Fang Zheng; Guangrong Zheng; A Gabriela Deaciuc; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2007-02-11       Impact factor: 3.641

4.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

5.  Pd-catalyzed enantioselective aerobic oxidation of secondary alcohols: applications to the total synthesis of alkaloids.

Authors:  Shyam Krishnan; Jeffrey T Bagdanoff; David C Ebner; Yeeman K Ramtohul; Uttam K Tambar; Brian M Stoltz
Journal:  J Am Chem Soc       Date:  2008-09-18       Impact factor: 15.419

Review 6.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system.

Authors:  Antoine Taly; Pierre-Jean Corringer; Denis Guedin; Pierre Lestage; Jean-Pierre Changeux
Journal:  Nat Rev Drug Discov       Date:  2009-09       Impact factor: 84.694

7.  Mannich-type Reactions of Cyclic Nitrones: Effective Methods for the Enantioselective Synthesis of Piperidine-containing Alkaloids.

Authors:  Vladislav G Lisnyak; Tessa Lynch-Colameta; Scott A Snyder
Journal:  Angew Chem Int Ed Engl       Date:  2018-10-19       Impact factor: 15.336

8.  Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.

Authors:  Guangrong Zheng; David B Horton; Narsimha Reddy Penthala; Justin R Nickell; John P Culver; Agripina G Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Medchemcomm       Date:  2013-03       Impact factor: 3.597

9.  (2S,6S)-1-Methyl-2,6-trans-distyryl-piperidinium chloride.

Authors:  Guangrong Zheng; Sean Parkin; Linda P Dwoskin; Peter A Crooks
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-12-09

10.  1-Methyl-2,6-cis-distyrylpiperidine.

Authors:  Guangrong Zheng; Sean Parkin; Linda P Dwoskin; Peter A Crooks
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.